Ffri Security Inc. (3692)

Overview

Hansoh Pharmaceutical Group Company Limited, rooted in its foundational years since 1995, stands as a beacon of innovation and excellence in the pharmaceutical landscape of the People's Republic of China. As an investment holding enterprise, its spectrum of activities spans the intricate process of research, development, production, and dissemination of pharmaceutical products geared towards addressing a myriad of health conditions. The organization's commitment to health and well-being is further accentuated by its collaborative efforts with globally recognized entities such as GlaxoSmithKline Intellectual Property (No.4) Limited, Biotheus Inc., and Merck Sharp & Dohme LLC (MSD). These partnerships emphasize Hansoh's dedication to pioneering advancements in therapeutic interventions, evidencing its prominence in the pharmaceutical sector. With its headquarters in Shanghai, China, and operating under the umbrella of Stellar Infinity Company Ltd., Hansoh Pharmaceutical Group embodies the essence of innovation, dedication, and excellence in healthcare.

Products and Services

Hansoh Pharmaceutical Group's product portfolio is a testament to its broad expertise across various therapeutic areas. Here's a closer look at some of its principal offerings:

• Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan: These flagship products tackle a range of conditions, from anti-infection to the treatment of central nervous system disorders, showcasing Hansoh's versatility in addressing diverse health issues.
• Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining: This suite of products further solidifies the company's stance in the anti-infection and central nervous system therapeutic areas, reflecting its continuous effort to enhance patient care and treatment outcomes.
• XINYUE: Symbolizing a significant stride in oncology, XINYUE represents Hansoh's commitment to combating cancer through innovative treatment solutions.
• Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc.: Catering to the metabolic diseases domain, these products exemplify Hansoh's drive towards addressing complex health conditions with precision and efficacy.

In addition to its rich product pipeline, Hansoh Pharmaceutical has forged strategic alliances to expand its therapeutic reach:

• With GlaxoSmithKline Intellectual Property (No.4) Limited: This collaboration is aimed at developing, manufacturing, and commercializing innovative treatments for extensive-stage small-cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
• With Biotheus Inc.: A partnership to develop, produce, and commercialize a bispecific antibody-drug conjugate product, demonstrating Hansoh's engagement in cutting-edge biopharmaceutical advancements.
• With Merck Sharp & Dohme LLC (MSD): This alliance focuses on the development, manufacture, and commercialization of HS-10535, a promising investigational pre-clinical oral small molecule in the glucagon-like peptide-1 (GLP-1) receptor agonist class for enhanced therapeutic interventions.